



Supplemental Figure S1

A



B



Supplemental Figure S1. Expression of bevacizumab and cediranib targets in endometrial cancer cells. (A) qRT-PCR for the bevacizumab ligand VEGF-A and cediranib targets VEGFR1, 2 and 3, FGFR1, 2 and 3, and PDGFR-α and PDGFR-β in Hec50 and KLE endometrial cancer cells. The lower the ΔC_t value, the higher the expression level. A ΔC_t value of 10-15 is indicative of robust mRNA expression, whereas values over 22 are very low expression (e.g., VEGFR2). N=3 (B) Protein levels in Hec50 cells as determined by Kinex™ KAM-1325 Phosphoproteomic Antibody Microarray. The repeat entries for certain receptors (e.g., VEGFR2) are reflective of different antibodies against different epitopes. Data were normalized to internal controls and calculated as the average normalized net signal (N=2). See also **Supplemental Table S2**.